| Mr Gregory Todd Mesna, MD | |
|
7407 Wayzata Blvd., St. Louis Park, MN 55426 | |
| (952) 927-4556 | |
| (952) 897-1360 |
| Full Name | Mr Gregory Todd Mesna |
|---|---|
| Gender | Male |
| Speciality | Plastic Surgery |
| Location | 7407 Wayzata Blvd., St. Louis Park, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679542070 | NPI | - | NPPES |
| P00088815 | Other | MN | RAILROAD MEDICARE |
| 01020301 | Other | MN | PREFERRED ONE |
| 13-11226 | Other | MN | MEDICA |
| 652888100 | Medicaid | MN | |
| 109283 | Other | MN | UCARE |
| 24T91ME | Other | MN | BLUE CROSS INDIV |
| 24T90SO | Other | MN | BLUE CROSS GROUP |
| MN652888100 | Medicaid | MN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 35064 (Minnesota) | Primary |
| Entity Name | North Memorial Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851344907 PECOS PAC ID: 0042123028 Enrollment ID: O20040122000470 |
News Archive
Accelitech LLC, the leader in the development and full-cycle management of technology-driven cancer treatment programs, is pleased to announce its inaugural proton therapy project. The treatment center project, now under development, is the latest in Accelitech's ongoing effort to bring leading treatment technologies to more patients through joint-venture partnerships with physicians and hospitals.
A 42-year-old investment banker arrives at the emergency department with complaints of nausea, vomiting, anxiety and tremor.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
Among older adults with subthreshold depression (insufficient levels of depressive symptoms to meet diagnostic criteria), collaborative care compared with usual care resulted in an improvement in depressive symptoms after four months, although it is of uncertain clinical importance, according to a study appearing in the February 21 issue of JAMA.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Gregory Todd Mesna, MD 7407 Wayzata Blvd., St. Louis Park, MN 55426 Ph: (952) 927-4556 | Mr Gregory Todd Mesna, MD 7407 Wayzata Blvd., St. Louis Park, MN 55426 Ph: (952) 927-4556 |
News Archive
Accelitech LLC, the leader in the development and full-cycle management of technology-driven cancer treatment programs, is pleased to announce its inaugural proton therapy project. The treatment center project, now under development, is the latest in Accelitech's ongoing effort to bring leading treatment technologies to more patients through joint-venture partnerships with physicians and hospitals.
A 42-year-old investment banker arrives at the emergency department with complaints of nausea, vomiting, anxiety and tremor.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.
Among older adults with subthreshold depression (insufficient levels of depressive symptoms to meet diagnostic criteria), collaborative care compared with usual care resulted in an improvement in depressive symptoms after four months, although it is of uncertain clinical importance, according to a study appearing in the February 21 issue of JAMA.
› Verified 8 days ago